Elaine Beed, MD
Medical Oncology · Cambridge, OHNPI 1326143777
Payments from drug & device makers
Across 56 payments — averaging $202.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$4K
- G1 Therapeutics, Inc.$2K
- Bayer$1K
- Novartis$940
- AstraZeneca$834
- Daiichi Sankyo Inc.$560
- plus $3K from 19 others
What the payments were for
- Consulting fees$5,90252%
- Speaking & faculty fees$2,05018%
- Food & beverage$2,71924%
- Education$6516%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 3 | $3,565 |
| G1 Therapeutics, Inc. | 1 | $1,500 |
| Bayer | 1 | $1,119 |
| Novartis | 1 | $940 |
| AstraZeneca(2 entities) | 9 | $834 |
| Daiichi Sankyo Inc. | 2 | $560 |
| Merck | 4 | $382 |
| Incyte Corporation | 3 | $339 |
| AbbVie | 4 | $338 |
| Seagen Inc. | 3 | $270 |
| Johnson & Johnson(2 entities) | 2 | $162 |
| Bristol Myers Squibb | 2 | $152 |
| Pfizer | 6 | $135 |
| Agios Pharmaceuticals, Inc. | 1 | $125 |
| Amgen | 2 | $123 |
| Exelixis Inc. | 1 | $112 |
| Astellas Pharma US Inc | 3 | $109 |
| Eisai Inc. | 1 | $108 |
| Tempus AI, Inc | 1 | $106 |
| Lilly USA, LLC | 1 | $100 |
| E.r. Squibb & Sons, L.L.C. | 1 | $78 |
| GSK | 1 | $76 |
| Caris MPI, Inc. | 1 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,322 in reported general payments places this provider in the 40th percentile of 157 medical oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 13 | $204 |
| Prednisone | 17 | $76 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Cambridge
- Michael WangBelpre$21.6M
- Kai HeColumbus$10.9M
- Timothy BurnsColumbus$7.2M
- Dwight OwenColumbus$6.8M
- Jennifer SelfridgeCleveland$6.3M
- Moshe OrnsteinCleveland$6.1M
- David CarboneColumbus$5.4M
- Manisha ShahColumbus$4.3M
- Gregory OttersonColumbus$4.1M
- Marcelo BonomiColumbus$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.